{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:02Z","timestamp":1781639702177,"version":"3.54.5"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018719","name":"Koc University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018719","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer is the most common malignancy among women, affecting nearly 1.5\u00a0million individuals worldwide every year. While survival rates improve, many reproductive-age survivors confront significant long-term consequences, particularly diminished ovarian reserve, infertility, and premature ovarian insufficiency due to the gonadotoxic effects of chemotherapy. Postponement of pregnancy for five years or more after treatment exacerbates the decline in fertility due to ongoing ovarian aging and depletion of residual ovarian reserve. Women carrying BRCA1\/2 mutations may already exhibit reduced ovarian reserve and are more vulnerable to gonadal damage, possibly due to impaired DNA repair mechanisms associated with these mutations. The contribution of other breast cancer susceptibility genes (e.g., ATM, CHEK2, PALB2, BARD1, RAD51C, RAD51D, and TP53) to chemotherapy-induced gonadotoxicity remains unclear. Although animal data shows depletion of primordial follicle pool and granulosa cells dysfunction, the ovarian effects of the poly(ADP-ribose) polymerase (PARP) inhibitors in women with and without BRCA mutation are not clear. Immune-check point inhibitors (ICIs) causes immune-mediated destruction of the primordial follicle pool and reduction in ovarian reserve. Cyclin dependent kinase inhibitors appear to be less toxic than ICIs. In this narrative review of the current literature we aimed to provide a comprehensive overview of the molecular mechanisms underlying ovarian toxicity associated with conventional chemotherapy and targeted therapies in breast cancer treatment.<\/jats:p>","DOI":"10.1007\/s43032-026-02067-x","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:18:50Z","timestamp":1772475530000},"page":"657-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Conventional Chemotherapy Regimens and Targeted Drugs on Ovarian Function in Breast Cancer Patients"],"prefix":"10.1007","volume":"33","author":[{"given":"Seyma","family":"Haskoylu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevval Berfin","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alara","family":"Alt\u0131ntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Bildik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Benlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-3886","authenticated-orcid":false,"given":"Ozgur","family":"Oktem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"1","key":"2067_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2067_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2067_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3857\/roj.2018.00290","volume":"36","author":"CB Dracham","year":"2018","unstructured":"Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018;36(2):85\u201394. https:\/\/doi.org\/10.3857\/roj.2018.00290.","journal-title":"Radiat Oncol J"},{"issue":"2","key":"2067_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.rbmo.2022.09.014","volume":"46","author":"S Yildiz","year":"2023","unstructured":"Yildiz S, Bildik G, Benlioglu C, Turan V, Dilege E, Ozel M, Oktem O. Breast cancer treatment and ovarian function. Reprod Biomed Online. 2023;46(2):313\u201331. https:\/\/doi.org\/10.1016\/j.rbmo.2022.09.014.","journal-title":"Reprod Biomed Online"},{"issue":"21","key":"2067_CR5","doi-asserted-by":"publisher","first-page":"10159","DOI":"10.1158\/0008-5472.CAN-07-2042","volume":"67","author":"O Oktem","year":"2007","unstructured":"Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007;67(21):10159\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2042.","journal-title":"Cancer Res"},{"issue":"10","key":"2067_CR6","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.23071","volume":"110","author":"O Oktem","year":"2007","unstructured":"Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110(10):2222\u20139. https:\/\/doi.org\/10.1002\/cncr.23071.","journal-title":"Cancer"},{"issue":"3","key":"2067_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/0041-008x(91)90310-b","volume":"107","author":"DR Plowchalk","year":"1991","unstructured":"Plowchalk DR, Mattison DR. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol. 1991;107(3):472\u2009\u2013\u200981 https:\/\/doi.org\/10.1016\/0041-008x(91)90310-b","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"2067_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/1097-0142(19901115)66:10<2099::AID-CNCR2820661010>3.0.CO;2-3","volume":"66","author":"MF Marcello","year":"1990","unstructured":"Marcello MF, Nuciforo G, Romeo R, Di Dino G, Russo I, Russo A, et al. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer. 1990;66(10):2099\u2013104.","journal-title":"Cancer"},{"issue":"6","key":"2067_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/humrep\/dem027","volume":"22","author":"D Meirow","year":"2007","unstructured":"Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22(6):1626\u201333. https:\/\/doi.org\/10.1093\/humrep\/dem027.","journal-title":"Hum Reprod"},{"issue":"12","key":"2067_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/humrep\/dev257","volume":"30","author":"G Bildik","year":"2015","unstructured":"Bildik G, Akin N, Senbabaoglu F, Sahin GN, Karahuseyinoglu S, Ince U, Oktem O. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod. 2015;30(12):2912\u201325. https:\/\/doi.org\/10.1093\/humrep\/dev257.","journal-title":"Hum Reprod"},{"issue":"9","key":"2067_CR11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1200\/JCO.1986.4.9.1405","volume":"4","author":"DC Doll","year":"1986","unstructured":"Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4(9):1405\u201317. https:\/\/doi.org\/10.1200\/JCO.1986.4.9.1405.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2067_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1634\/theoncologist.2012-0172","volume":"17","author":"I Ben-Aharon","year":"2012","unstructured":"Ben-Aharon I, Meizner I, Granot T, Uri S, Hasky N, Rizel S, Stemmer SM. Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Oncologist. 2012;17(11):1386\u201393. https:\/\/doi.org\/10.1634\/theoncologist.2012-0172.","journal-title":"Oncologist"},{"issue":"185","key":"2067_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005402","volume":"5","author":"L Kalich-Philosoph","year":"2013","unstructured":"Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, et al. Cyclophosphamide triggers follicle activation and \u201cburnout\u201d; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62. https:\/\/doi.org\/10.1126\/scitranslmed.3005402.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2067_CR14","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1371\/journal.pone.0070117","volume":"8","author":"S Morgan","year":"2013","unstructured":"Morgan S, Lopes F, Gourley C, Anderson RA, Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; Imatinib provides selective protection only against cisplatin. PLoS ONE. 2013;8(7):e70117. https:\/\/doi.org\/10.1371\/journal.pone.0070117.","journal-title":"PLoS ONE"},{"issue":"1","key":"2067_CR15","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1096\/fj.201801089R","volume":"33","author":"C Sonigo","year":"2019","unstructured":"Sonigo C, Beau I, Grynberg M, Binart N. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice. FASEB J. 2019;33(1):1278\u201387. https:\/\/doi.org\/10.1096\/fj.201801089R.","journal-title":"FASEB J"},{"issue":"6","key":"2067_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/humupd\/dmz027","volume":"25","author":"N Spears","year":"2019","unstructured":"Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, Klinger FG. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673\u201393. https:\/\/doi.org\/10.1093\/humupd\/dmz027.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"2067_CR17","first-page":"886","volume":"51","author":"AE Maccubbin","year":"1991","unstructured":"Maccubbin AE, Caballes L, Riordan JM, Huang DH, Gurtoo HL. A cyclophosphamide\/DNA phosphoester adduct formed in vitro and in vivo. Cancer Res. 1991;51(3):886\u201392.","journal-title":"Cancer Res"},{"issue":"1","key":"2067_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0009-2797(87)90020-2","volume":"61","author":"K Hemminki","year":"1987","unstructured":"Hemminki K. DNA-binding products of nornitrogen mustard, a metabolite of cyclophosphamide. Chem Biol Interact. 1987;61(1):75\u201388. https:\/\/doi.org\/10.1016\/0009-2797(87)90020-2.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"2067_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/toxsci\/kfy189","volume":"166","author":"JM Stringer","year":"2018","unstructured":"Stringer JM, Swindells EOK, Zerafa N, Liew SH, Hutt KJ. Multidose 5-fluorouracil is highly toxic to growing ovarian follicles in mice. Toxicol Sci. 2018;166(1):97\u2013107. https:\/\/doi.org\/10.1093\/toxsci\/kfy189.","journal-title":"Toxicol Sci"},{"issue":"5","key":"2067_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/bjc.1991.177","volume":"63","author":"AR Bianco","year":"1991","unstructured":"Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991;63(5):799\u2013803. https:\/\/doi.org\/10.1038\/bjc.1991.177.","journal-title":"Br J Cancer"},{"issue":"12","key":"2067_CR21","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.1990.8.12.2032","volume":"8","author":"MA Richards","year":"1990","unstructured":"Richards MA, O\u2019Reilly SM, Howell A, George WD, Fentiman IS, Chaudary MA, Rubens RD. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy\u2019s\/Manchester trial. J Clin Oncol. 1990;8(12):2032\u20139. https:\/\/doi.org\/10.1200\/JCO.1990.8.12.2032.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2067_CR22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718\u201329. https:\/\/doi.org\/10.1200\/JCO.1996.14.5.1718.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2067_CR23","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.ejca.2007.04.006","volume":"43","author":"A Partridge","year":"2007","unstructured":"Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from international breast cancer study group trials V and VI. Eur J Cancer. 2007;43(11):1646\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2007.04.006.","journal-title":"Eur J Cancer"},{"issue":"25","key":"2067_CR24","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1200\/JCO.2005.07.096","volume":"23","author":"WR Parulekar","year":"2005","unstructured":"Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National cancer Institute of Canada clinical trials group study\u2013NCIC CTG MA.5. J Clin Oncol. 2005;23(25):6002\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.07.096.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2067_CR25","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/annonc\/mdi241","volume":"16","author":"M Vanhuyse","year":"2005","unstructured":"Vanhuyse M, Fournier C, Bonneterre J. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol. 2005;16(8):1283\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdi241.","journal-title":"Ann Oncol"},{"issue":"8","key":"2067_CR26","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","volume":"16","author":"MN Levine","year":"1998","unstructured":"Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National cancer Institute of Canada clinical trials group. J Clin Oncol. 1998;16(8):2651\u20138. https:\/\/doi.org\/10.1200\/JCO.1998.16.8.2651.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2067_CR27","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","volume":"17","author":"PJ Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365\u201370. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2365.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2067_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdh266","volume":"15","author":"S Di Cosimo","year":"2004","unstructured":"Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Cognetti F. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004;15(7):1065\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdh266","journal-title":"Ann Oncol"},{"key":"2067_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2407-8-56","volume":"8","author":"M Berliere","year":"2008","unstructured":"Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, Machiels JP. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer. 2008;8:56. https:\/\/doi.org\/10.1186\/1471-2407-8-56.","journal-title":"BMC Cancer"},{"key":"2067_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1471-2407-10-281","volume":"10","author":"WB Zhou","year":"2010","unstructured":"Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, Wang S. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer. 2010;10:281. https:\/\/doi.org\/10.1186\/1471-2407-10-281.","journal-title":"BMC Cancer"},{"issue":"23","key":"2067_CR31","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/jnci\/dji398","volume":"97","author":"M Venturini","year":"2005","unstructured":"Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Bruzzi P. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97(23):1724\u201333. https:\/\/doi.org\/10.1093\/jnci\/dji398.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2067_CR32","doi-asserted-by":"publisher","first-page":"e42293","DOI":"10.1371\/journal.pone.0042293","volume":"7","author":"EC Roti Roti","year":"2012","unstructured":"Roti Roti EC, Leisman SK, Abbott DH, Salih SM. Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent. PLoS ONE. 2012;7(8):e42293. https:\/\/doi.org\/10.1371\/journal.pone.0042293.","journal-title":"PLoS ONE"},{"issue":"1","key":"2067_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/humrep\/det391","volume":"29","author":"F Li","year":"2014","unstructured":"Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, Oktay K. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum Reprod. 2014;29(1):107\u201313. https:\/\/doi.org\/10.1093\/humrep\/det391.","journal-title":"Hum Reprod"},{"issue":"8","key":"2067_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.18632\/aging.100363","volume":"3","author":"R Soleimani","year":"2011","unstructured":"Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging. 2011;3(8):782\u201393. https:\/\/doi.org\/10.18632\/aging.100363.","journal-title":"Aging"},{"issue":"5","key":"2067_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41419-023-05859-0","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Liu Q, Chang M, Pan Y, Yahaya BH, Liu Y, Lin J. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis. 2023;14(5):340. https:\/\/doi.org\/10.1038\/s41419-023-05859-0.","journal-title":"Cell Death Dis"},{"key":"2067_CR36","doi-asserted-by":"publisher","first-page":"E175","DOI":"10.5888\/pcd9.120092","volume":"9","author":"L Anderko","year":"2012","unstructured":"Anderko L, Roffenbender JS, Goetzel RZ, Howard J, Millard F, Wildenhaus K, Novelli W. Promoting prevention through the affordable care act: workplace wellness. Prev Chronic Dis. 2012;9:E175. https:\/\/doi.org\/10.5888\/pcd9.120092.","journal-title":"Prev Chronic Dis"},{"issue":"7","key":"2067_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","volume":"24","author":"JA Petrek","year":"2006","unstructured":"Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045\u201351. https:\/\/doi.org\/10.1200\/JCO.2005.03.3969.","journal-title":"J Clin Oncol"},{"key":"2067_CR38","first-page":"105","volume":"1","author":"GN Hortobagyi","year":"1986","unstructured":"Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson hospital and tumor Institute. NCI Monogr. 1986;1:105\u20139.","journal-title":"NCI Monogr"},{"issue":"13","key":"2067_CR39","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/cncr.25106","volume":"116","author":"P Sukumvanich","year":"2010","unstructured":"Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naughton MJ. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102\u201311. https:\/\/doi.org\/10.1002\/cncr.25106.","journal-title":"Cancer"},{"issue":"4","key":"2067_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.24835","volume":"116","author":"ME Abusief","year":"2010","unstructured":"Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791\u20138. https:\/\/doi.org\/10.1002\/cncr.24835.","journal-title":"Cancer"},{"issue":"3","key":"2067_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-005-9059-x","volume":"96","author":"WJ Kil","year":"2006","unstructured":"Kil WJ, Ahn SD, Shin SS, Lee SW, Choi EK, Kim JH, et al. Treatment-induced menstrual changes in very young (<\u200935 years old) breast cancer patients. Breast Cancer Res Treat. 2006;96(3):245\u201350. https:\/\/doi.org\/10.1007\/s10549-005-9059-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2067_CR42","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.5114\/aoms.2019.81730","volume":"15","author":"YY Kim","year":"2019","unstructured":"Kim YY, Kim WO, Liu HC, Rosenwaks Z, Kim JW, Ku SY. Effects of paclitaxel and cisplatin on in vitro ovarian follicle development. Arch Med Sci. 2019;15(6):1510\u20139. https:\/\/doi.org\/10.5114\/aoms.2019.81730.","journal-title":"Arch Med Sci"},{"issue":"1","key":"2067_CR43","first-page":"443","volume":"6","author":"ME Trudeau","year":"1996","unstructured":"Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 1996;6(1):443\u201357.","journal-title":"Can J Oncol"},{"issue":"1\u20132","key":"2067_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/s0027-5107(98)00228-0","volume":"423","author":"JB Mailhes","year":"1999","unstructured":"Mailhes JB, Carabatsos MJ, Young D, London SN, Bell M, Albertini DF. Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. Mutat Res. 1999;423(1\u20132):79\u201390. https:\/\/doi.org\/10.1016\/s0027-5107(98)00228-0.","journal-title":"Mutat Res"},{"key":"2067_CR45","doi-asserted-by":"publisher","first-page":"1025018","DOI":"10.3389\/fendo.2022.1025018","volume":"13","author":"C Wu","year":"2022","unstructured":"Wu C, Wu T, Chen D, Wei S, Tang W, Xue L, Wang S. The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence. Front Endocrinol (Lausanne). 2022;13:1025018. https:\/\/doi.org\/10.3389\/fendo.2022.1025018.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2067_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.coc.0000251398.57630.4f","volume":"30","author":"YL Tham","year":"2007","unstructured":"Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30(2):126\u201332. https:\/\/doi.org\/10.1097\/01.coc.0000251398.57630.4f.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"2067_CR47","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.fertnstert.2007.09.048","volume":"90","author":"A Reh","year":"2008","unstructured":"Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.09.048.","journal-title":"Fertil Steril"},{"issue":"2","key":"2067_CR48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10549-008-0071-9","volume":"115","author":"HS Han","year":"2009","unstructured":"Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Kim SW. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115(2):335\u201342. https:\/\/doi.org\/10.1007\/s10549-008-0071-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2067_CR49","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12282-011-0256-7","volume":"18","author":"Y Okanami","year":"2011","unstructured":"Okanami Y, Ito Y, Watanabe C, Iijima K, Iwase T, Tokudome N, Hatake K. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182\u20138. https:\/\/doi.org\/10.1007\/s12282-011-0256-7.","journal-title":"Breast Cancer"},{"issue":"8","key":"2067_CR50","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/cncr.21385","volume":"104","author":"MN Fornier","year":"2005","unstructured":"Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575\u20139. https:\/\/doi.org\/10.1002\/cncr.21385.","journal-title":"Cancer"},{"issue":"6","key":"2067_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3109\/0284186X.2016.1155738","volume":"55","author":"VA ZavosA","year":"2016","unstructured":"ZavosAVA. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol. 2016;55(6):664\u201370. . https:\/\/doi.org\/10.3109\/0284186X.2016.1155738","journal-title":"Acta Oncol"},{"issue":"6","key":"2067_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21(6):968\u201375. https:\/\/doi.org\/10.1200\/JCO.2003.04.040.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2067_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-008-9937-0Swain","volume":"113","author":"SR SwainSM, Land","year":"2009","unstructured":"SwainSM,Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113(2):315\u201320. . https:\/\/doi.org\/10.1007\/s10549-008-9937-0Swain","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2067_CR54","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.2010.29.7689","volume":"29","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Land SR, Geyer CE Jr., Cecchini RS, Costantino JP, Pajon ER, Swain SM. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29(9):1110\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.29.7689.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2067_CR55","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/gme.0b013e3181f3e6e7","volume":"18","author":"S Najafi","year":"2011","unstructured":"Najafi S, Djavid GE, Mehrdad N, Rajaii E, Alavi N, Olfatbakhsh A, Heidari K. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. Menopause. 2011;18(2):208\u201312. https:\/\/doi.org\/10.1097\/gme.0b013e3181f3e6e7.","journal-title":"Menopause"},{"issue":"5","key":"2067_CR56","doi-asserted-by":"publisher","first-page":"e37249","DOI":"10.1371\/journal.pone.0037249","volume":"7","author":"W Zhou","year":"2012","unstructured":"Zhou W, Ding Q, Liang X, He Z, Zha X, Liu X, Wang S. The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy. PLoS ONE. 2012;7(5):e37249. https:\/\/doi.org\/10.1371\/journal.pone.0037249.","journal-title":"PLoS ONE"},{"issue":"6","key":"2067_CR57","first-page":"1087","volume":"20","author":"JP Long","year":"2016","unstructured":"Long JP, Wan F, Zhang F, Zhou J, Don LF. DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer. Eur Rev Med Pharmacol Sci. 2016;20(6):1087\u201392.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"2067_CR58","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/GRF.0b013e3181f96e00","volume":"53","author":"KA Rodriguez-Wallberg","year":"2010","unstructured":"Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol. 2010;53(4):753\u201362. https:\/\/doi.org\/10.1097\/GRF.0b013e3181f96e00","journal-title":"Clin Obstet Gynecol"},{"issue":"8","key":"2067_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/OGX.0b013e3181f8c0aa","volume":"65","author":"O Oktem","year":"2010","unstructured":"Oktem O, Urman B. Options of fertility preservation in female cancer patients. Obstet Gynecol Surv. 2010;65(8):531\u201342. . https:\/\/doi.org\/10.1097\/OGX.0b013e3181f8c0aa","journal-title":"Obstet Gynecol Surv"},{"issue":"9","key":"2067_CR60","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.2005.03.0783","volume":"24","author":"M Colleoni","year":"2006","unstructured":"Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Gelber RD. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13\u201393. J Clin Oncol. 2006;24(9):1332\u201341.JCO.2005.03.0783https:\/\/doi.org\/10.1200\/jco.2005.03.0783","journal-title":"J Clin Oncol"},{"issue":"1","key":"2067_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10549-015-3511-3","volume":"153","author":"AJ Chien","year":"2015","unstructured":"Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Rosen MP. Association of Tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015;153(1):173\u201381. https:\/\/doi.org\/10.1007\/s10549-015-3511-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2067_CR62","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-014-2914-x","volume":"145","author":"J Zhao","year":"2014","unstructured":"Zhao J, Liu J, Chen K, Li S, Wang Y, Yang Y, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113\u201328. https:\/\/doi.org\/10.1007\/s10549-014-2914-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"2067_CR63","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/humrep\/den248","volume":"23","author":"M Rosendahl","year":"2008","unstructured":"Rosendahl M, Andersen CY, Ernst E, Westergaard LG, Rasmussen PE, Loft A, Andersen AN. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod. 2008;23(11):2475\u201383. https:\/\/doi.org\/10.1093\/humrep\/den248.","journal-title":"Hum Reprod"},{"issue":"1","key":"2067_CR64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10549-020-05933-7","volume":"185","author":"SB Goldfarb","year":"2021","unstructured":"Goldfarb SB, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Oktay KH. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Res Treat. 2021;185(1):165\u201373. https:\/\/doi.org\/10.1007\/s10549-020-05933-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2067_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/humrep\/deg045","volume":"18","author":"K Oktay","year":"2003","unstructured":"Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with Tamoxifen. Hum Reprod. 2003;18(1):90\u20135. https:\/\/doi.org\/10.1093\/humrep\/deg045.","journal-title":"Hum Reprod"},{"issue":"19","key":"2067_CR66","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","volume":"23","author":"K Oktay","year":"2005","unstructured":"Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347\u201353. https:\/\/doi.org\/10.1200\/JCO.2005.05.037.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2067_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jnci\/djy094","volume":"111","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, de Azambuja E. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and survival in premenopausal HER2-Positive early breast cancer patients. J Natl Cancer Inst. 2019;111(1):86\u201394. https:\/\/doi.org\/10.1093\/jnci\/djy094.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2067_CR68","first-page":"1763","volume":"20","author":"SR Morris","year":"2006","unstructured":"Morris SR, Carey LA. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer. Oncology. 2006;20(14):1763\u201371. discussion 1771-2, 1774-6.","journal-title":"Oncology"},{"issue":"1","key":"2067_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/humupd\/dmx029","volume":"24","author":"D Richani","year":"2018","unstructured":"Richani D, Gilchrist RB. The epidermal growth factor network: role in oocyte growth, maturation and developmental competence. Hum Reprod Update. 2018;24(1):1\u201314. https:\/\/doi.org\/10.1093\/humupd\/dmx029.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"2067_CR70","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.3747\/co.24.3335","volume":"24","author":"K Morarji","year":"2017","unstructured":"Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, Hodgson DC. Ovarian function after chemotherapy in young breast cancer survivors. Curr Oncol. 2017;24(6):e494\u2013502. https:\/\/doi.org\/10.3747\/co.24.3335.","journal-title":"Curr Oncol"},{"issue":"1","key":"2067_CR71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41523-021-00264-2","volume":"7","author":"PA Ganz","year":"2021","unstructured":"Ganz PA, Cecchini RS, Fehrenbacher L, Geyer CE Jr., Rastogi P, Crown JP, Wolmark N. NRG Oncology\/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. NPJ Breast Cancer. 2021;7(1):55. https:\/\/doi.org\/10.1038\/s41523-021-00264-2.","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"2067_CR72","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","volume":"151","author":"KJ Ruddy","year":"2015","unstructured":"Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589\u201396. https:\/\/doi.org\/10.1007\/s10549-015-3426-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2067_CR73","doi-asserted-by":"publisher","first-page":"e013053","DOI":"10.1136\/bmjopen-2016-013053","volume":"7","author":"ZQ Xu","year":"2017","unstructured":"Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, Tie XJ. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e013053. https:\/\/doi.org\/10.1136\/bmjopen-2016-013053.","journal-title":"BMJ Open"},{"issue":"26","key":"2067_CR74","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733\u201343. https:\/\/doi.org\/10.1056\/NEJMoa064320.","journal-title":"N Engl J Med"},{"issue":"6","key":"2067_CR75","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.fertnstert.2012.12.040","volume":"99","author":"E Nagyova","year":"2013","unstructured":"Nagyova E, Nemcova L, Mlynarcikova A, Scsukova S, Kalous J. Lapatinib inhibits meiotic maturation of Porcine oocyte-cumulus complexes cultured in vitro in gonadotropin-supplemented medium. Fertil Steril. 2013;99(6):1739\u201348. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.12.040.","journal-title":"Fertil Steril"},{"issue":"1","key":"2067_CR76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-021-06267-8","volume":"189","author":"KJ Ruddy","year":"2021","unstructured":"Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to Paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021;189(1):103\u201310. https:\/\/doi.org\/10.1007\/s10549-021-06267-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"2067_CR77","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","volume":"41","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Meric-Bernstam F. Efficacy of trastuzumab Deruxtecan in HER2-Expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-PanTumor02. Adv Ther. 2024;41(11):4125\u201339. https:\/\/doi.org\/10.1007\/s12325-024-02975-x.","journal-title":"Adv Ther"},{"issue":"5","key":"2067_CR78","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdy099.","journal-title":"Ann Oncol"},{"issue":"12","key":"2067_CR79","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/cncr.31307","volume":"124","author":"AA Turk","year":"2018","unstructured":"Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124(12):2498\u2013506. https:\/\/doi.org\/10.1002\/cncr.31307.","journal-title":"Cancer"},{"issue":"3","key":"2067_CR80","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/RAF-22-0020","volume":"3","author":"R Rosario","year":"2022","unstructured":"Rosario R, Cui W, Anderson RA. Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. Reprod Fertil. 2022;3(3):R147\u201362. https:\/\/doi.org\/10.1530\/RAF-22-0020","journal-title":"Reprod Fertil"},{"issue":"8","key":"2067_CR81","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/humrep\/deaa128","volume":"35","author":"AL Winship","year":"2020","unstructured":"Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020;35(8):1864\u201374. https:\/\/doi.org\/10.1093\/humrep\/deaa128.","journal-title":"Hum Reprod"},{"issue":"1","key":"2067_CR82","doi-asserted-by":"publisher","first-page":"17058","DOI":"10.1038\/s41598-020-74087-9","volume":"10","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Takae S, Shiraishi E, Shinya K, Igualada AJ, Suzuki N. Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells. Sci Rep. 2020;10(1):17058. https:\/\/doi.org\/10.1038\/s41598-020-74087-9.","journal-title":"Sci Rep"},{"issue":"1","key":"2067_CR83","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae108.367","volume":"39","author":"E Iltumur","year":"2024","unstructured":"Iltumur E, Esmaeilian Y, Oktem O. O-310\u2003PARP inhibitors have no toxic effect on follicle reserve, mitotic and steroidogenic function of granulosa cells in human ovary. Hum Reprod. 2024;39(1):deae108.367. https:\/\/doi.org\/10.1093\/humrep\/deae108.367.","journal-title":"Hum Reprod"},{"key":"2067_CR84","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad045","author":"S Johnston","year":"2023","unstructured":"Johnston S, Emde A, Barrios C, Srock S, Neven P, Martin M, et al. Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors: existing and emerging differences. JNCI Cancer Spectr. 2023. https:\/\/doi.org\/10.1093\/jncics\/pkad045.","journal-title":"JNCI Cancer Spectr"},{"key":"2067_CR85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.reprotox.2019.07.016","volume":"88","author":"NR Catlin","year":"2019","unstructured":"Catlin NR, Bowman CJ, Engel SM, Sacaan A, Thibault S, Lewis EM, Cappon GD. Reproductive and developmental toxicity assessment of palbociclib, a CDK4\/6 inhibitor, in Sprague-Dawley rats and new Zealand white rabbits. Reprod Toxicol. 2019;88:76\u201384. https:\/\/doi.org\/10.1016\/j.reprotox.2019.07.016.","journal-title":"Reprod Toxicol"},{"key":"2067_CR86","doi-asserted-by":"publisher","unstructured":"Kalajahi HG YS, Benlioglu C, Albayrak O, Oktem O, Cyclin-Dependent Kinase (CDK) Inhibitors are not detrimental to dormant follicles and steroidogenic function in human ovary. Human Reprod, 2025. 40(10):deaf097.265. https:\/\/doi.org\/10.1093\/humrep\/deaf097.265.","DOI":"10.1093\/humrep\/deaf097.265"},{"key":"2067_CR87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","volume":"79","author":"N Gaynor","year":"2022","unstructured":"Gaynor N, Crown J, Collins DM. Immune checkpoint inhibitors: key trials and an emerging role in breast cancer. Semin Cancer Biol. 2022;79:44\u201357. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.016.","journal-title":"Semin Cancer Biol"},{"key":"2067_CR88","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.ctrv.2024.102831","volume":"130","author":"F Rebaudi","year":"2024","unstructured":"Rebaudi F, De Franco F, Goda R, Obino V, Vita G, Baronti C, Marcenaro E. The landscape of combining immune checkpoint inhibitors with novel therapies: secret alliances against breast cancer. Cancer Treat Rev. 2024;130:102831. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102831.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2067_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","volume":"3","author":"AL Winship","year":"2022","unstructured":"Winship AL, Alesi LR, Sant S, Stringer JM, Cantavenera A, Hegarty T, Hutt KJ. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer. 2022;3(8):1\u201313. https:\/\/doi.org\/10.1038\/s43018-022-00413-x.","journal-title":"Nat Cancer"},{"key":"2067_CR90","doi-asserted-by":"publisher","first-page":"12013","DOI":"10.1200\/JCO.2023.41.16_suppl.12013","volume":"41","author":"E Buchbinder","year":"2023","unstructured":"Buchbinder E, Song Z, Lee S, Keefe K, Manos M, Tarhini A, et al. Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial. J Clin Oncol. 2023;41:12013\u201312013. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.12013.","journal-title":"J Clin Oncol"},{"key":"2067_CR91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","volume":"152","author":"M Salzmann","year":"2021","unstructured":"Salzmann M, Tosev G, Heck M, Schadendorf D, Maatouk I, Enk AH, et al. Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study. Eur J Cancer. 2021;152:41\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.031.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2067_CR92","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","volume":"6","author":"JM Scovell","year":"2020","unstructured":"Scovell JM, Benz K, Samarska I, Kohn TP, Hooper JE, Matoso A, Herati AS. Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma. JAMA Oncol. 2020;6(8):1297\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1641.","journal-title":"JAMA Oncol"},{"key":"2067_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaf097.265","author":"H Ghafouri Kalajahi","year":"2025","unstructured":"Ghafouri Kalajahi H, Yusufoglu S, Benlioglu C, Albayrak O, Oktem O. O-265 Cyclin-Dependent kinase (CDK) inhibitors are not detrimental to dormant follicles and steroidogenic function in human ovary. Hum Reprod. 2025. https:\/\/doi.org\/10.1093\/humrep\/deaf097.265. 40(Supplement_1).","journal-title":"Hum Reprod"},{"issue":"12","key":"2067_CR94","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/biomedicines8120577","volume":"8","author":"M Levi","year":"2020","unstructured":"Levi M, Goshen-Lago T, Yerushalmi R, Granot T, Stemmer SM, Shalgi R, Ben-Aharon I. Anti-HER2\/neu antibody reduces chemotherapy-induced ovarian toxicity\u2014from bench to bedside. Biomedicines. 2020;8(12):577. https:\/\/doi.org\/10.3390\/biomedicines8120577.","journal-title":"Biomedicines"},{"issue":"3","key":"2067_CR95","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/or.2020.7660","volume":"44","author":"Q Liao","year":"2020","unstructured":"Liao Q, Feng X, Li X, Chen G, Chen J, Yang B, et al. Lapatinib\u2013induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro. Oncol Rep. 2020;44(3):1127\u201335. https:\/\/doi.org\/10.3892\/or.2020.7660.","journal-title":"Oncol Rep"},{"issue":"1","key":"2067_CR96","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1038\/s41598-025-91476-0","volume":"15","author":"B Koylu","year":"2025","unstructured":"Koylu B, Esen BH, Bektas SN, Ozbek L, Turan V, Urman B, Selcukbiricik F. Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system. Sci Rep. 2025;15(1):7770. https:\/\/doi.org\/10.1038\/s41598-025-91476-0.","journal-title":"Sci Rep"},{"issue":"5","key":"2067_CR97","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"C Breast Cancer Association","year":"2021","unstructured":"Breast Cancer Association C, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Easton DF. Breast cancer risk Genes - Association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1913948.","journal-title":"N Engl J Med"},{"issue":"31","key":"2067_CR98","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2012.47.7893","volume":"31","author":"A Valentini","year":"2013","unstructured":"Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.47.7893.","journal-title":"J Clin Oncol"},{"key":"2067_CR99","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fonc.2019.00575","volume":"9","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, Clatot F. Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-m\u00fcllerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy. Front Oncol. 2019;9:575. https:\/\/doi.org\/10.3389\/fonc.2019.00575.","journal-title":"Front Oncol"},{"key":"2067_CR100","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.breast.2021.09.006","volume":"60","author":"ML Gasparri","year":"2021","unstructured":"Gasparri ML, Di Micco R, Zuber V, Taghavi K, Bianchini G, Bellaminutti S, Gentilini OD. Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis. Breast. 2021;60:155\u201362. https:\/\/doi.org\/10.1016\/j.breast.2021.09.006.","journal-title":"Breast"},{"issue":"18","key":"2067_CR101","doi-asserted-by":"publisher","first-page":"19225","DOI":"10.1002\/cam4.6527","volume":"12","author":"KH Oktay","year":"2023","unstructured":"Oktay KH, Turan V, Bedoschi G, Abdo N, Bang H, Goldfarb S. A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: impact of BRCA pathogenic variants. Cancer Med. 2023;12(18):19225\u201333. https:\/\/doi.org\/10.1002\/cam4.6527.","journal-title":"Cancer Med"},{"issue":"18","key":"2067_CR102","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1200\/JCO.20.02880","volume":"39","author":"V Turan","year":"2021","unstructured":"Turan V, Lambertini M, Lee DY, Wang E, Clatot F, Karlan BY, et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. J Clin Oncol. 2021;39(18):2016\u201324. https:\/\/doi.org\/10.1200\/JCO.20.02880.","journal-title":"J Clin Oncol"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-026-02067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-026-02067-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-026-02067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:18:23Z","timestamp":1781637503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-026-02067-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2067"],"URL":"https:\/\/doi.org\/10.1007\/s43032-026-02067-x","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}